Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hualan Biological Bacterin Inc. (301207.SZ)
Xinxiang, CN
Hualan Biological Bacterin Inc. is a Chinese pharmaceutical company focused on the entire vaccine lifecycle, from research and development to manufacturing and sales within China. The company's product line features a diverse range of immunizations, including various influenza virus vaccines (such as split, quadrivalent, and H1N1 strains), recombinant hepatitis B vaccines, and meningococcal polysaccharide vaccines (including ACYW135 and Group A & C types). They also develop genetically engineered vaccines for human use. Established in 2005, Hualan Biological Bacterin Inc. is headquartered in Xinxiang, China, and previously operated as a subsidiary of Hualan Biological Engineering Inc.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.24% | -5.56% | -7.59% | -12.95% | -21.89% | -3.27% | +7.58% | -47.36% | -61.55% | -61.55% | -61.55% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+6.2% ★ Q1'26: +10.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-8.8% Q1'26: +14.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+20.1% Q1'26: +837.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+7.5% ★ Q1'26: -76.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+2.9% ★ Q1'26: -2.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.5% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.04× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
1.83B
est: 2.30B (-20.4%)
|
1.83B
est: 2.30B (-20.5%)
|
2.41B
est: 2.30B (+5.0%)
|
1.13B
est: 1.60B (-29.5%)
|
1.20B
est: 1.82B (-34.1%)
|
1.40B
1.40B – 1.40B
-23.1% YoY
|
1.60B
1.60B – 1.60B
+14.4% YoY
|
1.79B
1.79B – 1.79B
+11.9% YoY
|
| EBITDA |
787.17M
est: 845.25M (-6.9%)
|
734.72M
est: 837.98M (-12.3%)
|
1.15B
est: 837.98M (+37.6%)
|
361.13M
est: 583.87M (-38.1%)
|
231.53M
est: 663.05M (-65.1%)
|
510.15M
510.15M – 510.15M
-23.1% YoY
|
583.87M
583.87M – 583.87M
+14.4% YoY
|
653.20M
653.20M – 653.20M
+11.9% YoY
|
| EBIT |
719.26M
est: 702.60M (+2.4%)
|
600.30M
est: 649.08M (-7.5%)
|
1.01B
est: 649.08M (+56.1%)
|
220.76M
est: 452.25M (-51.2%)
|
90.30M
est: 513.59M (-82.4%)
|
395.16M
395.16M – 395.16M
-23.1% YoY
|
452.25M
452.25M – 452.25M
+14.4% YoY
|
505.96M
505.96M – 505.96M
+11.9% YoY
|
| Net Income |
620.97M
est: 797.50M (-22.1%)
|
519.63M
est: 769.35M (-32.5%)
|
859.97M
est: 769.35M (+11.8%)
|
205.52M
est: 214.20M (-4.1%)
|
182.92M
est: 636.65M (-71.3%)
|
214.20M
214.20M – 214.20M
-66.4% YoY
|
255.85M
255.85M – 255.85M
+19.4% YoY
|
309.40M
309.40M – 309.40M
+20.9% YoY
|
| SGA |
647.50M
est: 963.52M (-32.8%)
|
776.35M
est: 1.03B (-24.4%)
|
1.02B
est: 1.03B (-0.8%)
|
582.54M
est: 715.39M (-18.6%)
|
619.77M
est: 812.42M (-23.7%)
|
625.07M
625.07M – 625.07M
-23.1% YoY
|
715.39M
715.39M – 715.39M
+14.4% YoY
|
800.34M
800.34M – 800.34M
+11.9% YoY
|
| EPS |
1.15
est: 1.33 (-13.7%)
|
0.88
est: 1.29 (-31.9%)
|
1.43
est: 1.29 (+10.6%)
|
0.34
est: 0.36 (-5.6%)
|
0.31
est: 1.07 (-71.0%)
|
0.36
0.36 – 0.36
-66.4% YoY
|
0.43
0.43 – 0.43
+19.4% YoY
|
0.52
0.52 – 0.52
+20.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-27 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-26 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-25 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-22 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-21 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-20 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-19 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-18 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-15 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.02% | 122.2K | 0.65% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 204.5K | 0.06% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 15.1K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 6.7K | 0.48% |
| 5 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 743.3K | 0.06% |
| 6 | Vanguard ESG International Stock ETF VSGX | 0.00% | 16.5K | 0.10% |
| 7 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.00M | 0.05% |
| 8 | Vanguard Total World Stock ETF VT | 0.00% | 64.1K | 0.06% |
| 9 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 1.2K | 0.22% |
| 10 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 3.6K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ke Lu | Chief Financial Officer & Secretary | — | male |
| Ruowen Pan | Executive Vice President & Director | — | female |
| Wenjue An | GM & Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 301207.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
